文献速递消化系统肿瘤

将BEAMing液体活检纳入结直肠癌临床管理:专家工作组综述

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
PubMed 文献 · Ann Oncol · 2017-01-01

晚期结直肠癌抗EGFR治疗需明确RAS突变状态,但组织检测存在周转延迟、样本质量差和标准化不足等问题。BEAMing技术检测循环肿瘤DNA突变可快速提供扩展RAS检测结果,OncoBEAM RAS结直肠癌检测与标准组织检测总体一致性达93.3%。本文概述该微创方法的临床效用和潜在应用,如早期发现抗EGFR治疗耐药。

要点

  • BEAMing液体活检可快速提供扩展RAS检测,弥补组织检测的不足。
  • OncoBEAM RAS结直肠癌检测与标准组织检测总体一致性为93.3%。
  • 该微创方法潜在应用于早期发现抗EGFR治疗耐药。

核心结论

  • BEAMing技术检测循环肿瘤DNA突变可弥补组织检测不足,使患者快速获得指南推荐的扩展RAS检测结果。
  • OncoBEAM RAS结直肠癌检测与标准组织检测总体一致性很高(93.3%)。
  • 若适当实施,BEAMing技术有望提高患者护理质量和改善临床结局。

研究设计与样本

  • 专家工作组综述,概述BEAMing液体活检的临床效用和潜在应用。

主要发现

  • OncoBEAM RAS结直肠癌检测与标准组织检测的总体一致性为93.3%。
  • BEAMing技术可快速周转提供扩展RAS检测,弥补组织检测延迟、低质量和缺乏标准化的问题。
  • 该微创方法潜在应用于早期发现抗EGFR治疗耐药。

临床怎么用

  • BEAMing技术可作为液体活检纳入临床实践,为晚期结直肠癌患者提供快速扩展RAS检测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. García-Foncillas J, Alba E, Aranda E, et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. 2017. PMID: 28945877. doi:10.1093/annonc/mdx501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。